Physician profile
David Zachary Gay
NPI 1497054605
$92,874.93
in general payments reported to CMS, 2019-2025
19 companies · $26K in 2025
The $26K reported for 2025 was more than what 96% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $207 · 2021: $10K · 2022: $13K · 2023: $22K · 2024: $20K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Honoraria: $19K · Travel and Lodging: $11K · Consulting Fee: $5,100 · Food and Beverage: $4,098 · Education: $10.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,175.00 |
| Honoraria | $18,875.00 |
| Travel and Lodging | $10,547.40 |
| Consulting Fee | $5,100.00 |
| Food and Beverage | $4,097.89 |
| Education | $10.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $45,610.95 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $44,988.39 | 2020-2023 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $410.90 | 2019-2021 | |
| Biotissue Holdings INC. | $204.86 | 2019-2020 | |
| New World Medical,INC. | $199.65 | 2024 | Clearpath, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Heidelberg Engineering, INC. | $184.27 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $163.21 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $143.19 | 2025 | Centurion |
| Merz North America, INC. | $131.84 | 2019 | |
| Sight Sciences, INC. | $126.54 | 2025 | Omni Surgical System |
| Ocular Therapeutix, INC. | $124.44 | 2021 | |
| Mallinckrodt Hospital Products INC. | $118.95 | 2024 | Acthar |
| Aerie Pharmaceuticals, INC. | $117.87 | 2019 | |
| Optovue, INC. | $100.00 | 2019 | |
| Rxsight INC | $80.74 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acelrx Pharmaceuticals, INC. | $74.77 | 2021 | |
| Revance Therapeutics, INC. | $35.00 | 2024 | Daxxify |
| Eyepoint US, INC. | $34.45 | 2021 | |
| Integra Lifesciences Corporation | $24.91 | 2023 | Integra, Omnigraft, Surgimend |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.